(CercleFinance.com) – Asklepios BioPharmaceutical (AskBio), a wholly owned and independently operated gene therapy company as a subsidiary of Bayer, announces first patient randomized in Phase 1 AB- gene therapy trial 1005 (AAV2-GDNF) for multiple system atrophy parkinsonian type (MSA-P).
AB-1005 is also currently being studied for the treatment of mild to moderate Parkinson’s disease, with enrollment in the Phase 1b study now complete.
This marks an important milestone in the development of AB -1005, an adeno-associated viral vector encoding glial cell line-derived neurotrophic factor (AAV2-GDNF) that is delivered to the putamen, and brings this therapeutic one step closer to a potential goal of reaching patients.
“It means a lot to the MSA community to know that the first patient has been enrolled in the Phase 1 REGENERATE MSA-101 trial,” said Philip M. Fortier, MA, president and executive director of Defeat MSA Alliance.
‘There is no cure for MSA, and there is currently no treatment to stop or slow the progression of the disease. This makes it particularly difficult for patients, given the rapid decline many will experience. We hope that today’s milestone brings us closer to a potential change in outcomes for patients with SMA.’
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
